Skip to main content

Table 2 Participants characteristics

From: MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy

Characteristics

Primary analysis cohort

Subgroup analysis cohort

1st-timepoint subgroup

2nd-timepoint subgroup

n = 345a

n = 245

p

n = 207

p

Age (year), IQR

51 (42, 58)

51 (42, 58)

0.865

50 (41, 58)

0.427

Tumor size (mm), IQR

37 (27, 49)

36 (27, 49)

0.786

37 (28, 49)

0.965

Menopausal status

0.595

 

0.947

 Premenopausal

174 (50)

129 (53)

 

105 (51)

 

 Postmenopausal

171 (50)

116 (47)

 

102 (49)

 

TNM

0.726

 

0.839

 IIA

64 (19)

49 (20)

 

33 (16)

 

 IIB

127 (37)

79 (32)

 

84 (41)

 

 IIIA

50 (15)

33 (14)

 

31 (15)

 

 IIIB

27 (7.8)

24 (10)

 

13 (6.3)

 

 IIIC

77 (22)

60 (25)

 

46 (22)

 

Histologic grade

0.619

 

0.427

 2

239 (69)

165 (67)

 

150 (73)

 

 3

106 (31)

80 (33)

 

57 (28)

 

Molecular subtype

0.747

 

0.871

 HR+/HER2−

151 (44)

100 (41)

 

94 (45)

 

 HER2+

123 (36)

94 (38)

 

74 (36)

 

 TNBC

71 (21)

51 (21)

 

39 (19)

 

NAT regimen

0.763

 

0.943

 Anthracycline-based

29 (8.4)

17 (7.1)

 

16 (7.7)

 

 Taxane-based

123 (36)

92 (38)

 

76 (37)

 

 Anthracycline and taxane-based

193 (56)

136 (56)

 

115 (56)

 

Treatment response

0.855

 

0.888

 pCR

113 (33)

82 (33)

 

69 (33)

 

 Non-pCR

232 (67)

163 (67)

 

138 (67)

 

FGT

0.747

 

0.787

 Scattered

70 (20)

51 (21)

 

39 (19)

 

 Heterogeneously

211 (61)

143 (58)

 

125 (60)

 

 Extremely dense

64 (19)

51 (21)

 

43 (21)

 

BPE

0.860

 

0.404

 Minimal

35 (10)

29 (12)

 

14 (6.8)

 

 Mild

192 (56)

139 (57)

 

113 (55)

 

 Moderate

88 (26)

58 (24)

 

56 (27)

 

 Marked

30 (8.7)

19 (7.8)

 

24 (12)

 

Enhancement type

0.756

 

0.716

 Mass

281 (81)

202 (82)

 

166 (80)

 

 Non-mass

64 (19)

43 (18)

 

41 (20)

 

Multiplicity

0.521

 

0.190

 Single lesion

129 (37)

98 (40)

 

66 (32)

 

 Multi-lesion

216 (63)

147 (60)

 

141 (68)

 

Shape

0.491

 

0.595

 Round or oval

68 (20)

54 (22)

 

37 (18)

 

 Irregular

277 (80)

191 (78)

 

170 (82)

 

Margin

0.688

 

0.735

 Circumscribed

24 (7.0)

15 (6.1)

 

16 (7.7)

 

 Not circumscribed

321 (93)

230 (94)

 

191 (92)

 

Kinetics

0.962

 

0.896

 Persistent

8 (2.3)

5 (2.0)

 

4 (1.9)

 

 Plateau

123 (36)

86 (35)

 

71 (34)

 

 Washout

214 (62)

154(63)

 

132 (64)

 
  1. Unless otherwise specified, data are numbers of participants, with percentages in parentheses
  2. p values show the results of comparisons between the participants in the subgroup cohorts versus the participants in the primary analysis cohort
  3. pCR pathologic complete response, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer, HR hormone receptor, NAT neoadjuvant therapy, BPE background parenchymal enhancement, FGT fibroglandular tissue
  4. a345 MRI including 138 1st-MRI and 207 2nd-MRI
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us